Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently ...

Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...

The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after President Donald Trump dramatically cut global aid.

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange ...

The Pennsylvania Department of Health will cut 25% of funding to the Part B of the Ryan White HIV/AIDS Program amid rising ...

UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...

Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader ...

Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do not stay within national boundaries. Increased rates of untreated HIV in ...

The Trump administration’s new global HIV prevention strategy prioritizes preventing mother-to-child HIV transmission. About 120,000 children under the age of 5 were newly infected with HIV in 2024, ...